Cemdisiran in Myasthenia Gravis: Hospitalization Findings Bring Pharmacist Priorities Into Focus

For patients with generalized myasthenia gravis (gMG), treatment success extends beyond improvements on symptom scales. Avoiding a myasthenic crisis or prolonged hospitalization can have substantial consequences for patients’ overall health, particularly when other medical conditions complicate recovery. In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, explained how hospitalization findings from NIMBLE provide additional context for investigational cemdisiran—and where pharmacists could contribute if the therapy is approved.

Cemdisiran is a small interfering RNA (siRNA) therapy that reduces hepatic production of complement component 5 (C5). In the phase 3 NIMBLE trial (NCT05070858), subcutaneous administration every 12 weeks improved patient-reported daily functioning compared with placebo. At week 24, the placebo-adjusted improvement in the Myasthenia Gravis–Activities of Daily Living score was 2.3 points, meeting the primary endpoint.¹

Hospitalizations Add Clinical Context

“Myasthenic crisis is the most severe manifestation of myasthenia for an individual,” Habib said.

Although preventing deterioration is a central treatment goal, crisis events are relatively uncommon during the limited observation periods of clinical trials. Habib explained that hospitalization outcomes can therefore help clinicians understand disease burden alongside symptom measures, even when they are not primary outcomes.

“A lot of our patients are older individuals with other diseases, so hospitalizations can have a big impact on their overall health as well as their myasthenia,” he said.

Discussing NIMBLE’s 24-week double-blind period, Habib described numerically fewer patients with worsening disease progressing to impending myasthenic crisis or crisis in the cemdisiran group than in the placebo group. He also noted fewer hospitalizations overall and a numerically shorter duration of hospitalization with cemdisiran. The trial’s published results announcement similarly reported numerically lower rates of hospitalization, myasthenic crisis, and rescue therapy with treatment.¹

Those findings require careful interpretation. Habib repeatedly emphasized the small event numbers and characterized the observations as supportive evidence, rather than the trial’s primary measure of efficacy.

“These are important supportive findings and encouraging findings,” he said.

For pharmacists discussing emerging options, that distinction helps keep patient expectations aligned with the evidence: favorable hospitalization observations complement demonstrated symptom improvement but do not guarantee that an individual patient will avoid a crisis.

A Different Approach to Complement Targeting

Habib explained that cemdisiran acts at the site of C5 production in the liver, whereas existing C5-targeting therapies act on the protein already present in circulation. Its every-12-week administration schedule could also lessen the practical burden of ongoing treatment.¹

“What that means for patients is very infrequent dosing with potential for sustained benefit,” he said.

Cemdisiran remains investigational. The FDA accepted its application under priority review, with a target action date in November 2026, for adults with anti-acetylcholine receptor (AChR) antibody–positive gMG.²

Trial eligibility and a proposed indication are distinct. NIMBLE’s listed criteria permitted adults with AChR or low-density lipoprotein receptor–related protein 4 (LRP4) antibodies. Habib noted that MuSK antibody–positive and seronegative patients were excluded.³

Pharmacists Can Strengthen Infection-Risk Counseling

Complement targeting also raises infection-prevention considerations. Habib emphasized the importance of explaining that vaccination does not eliminate infection risk.

“It’s important to educate patients that the risk is not zero, even if you are fully vaccinated,” he said.

CDC guidance for complement inhibitor recipients recommends both MenACWY and MenB vaccination, with ongoing boosters. It also calls for counseling patients to seek immediate care for symptoms of meningococcal disease, including when vaccination is current. These are class-level recommendations, rather than an approved cemdisiran-specific prescribing framework.⁴

Habib identified vaccination tracking as a practical challenge and an opportunity for pharmacists. He also encouraged checking that patients receiving complement inhibition carry safety cards documenting infection risk, particularly when they seek emergency care.

Clinical Practice Will Shape Treatment Decisions

Determining where cemdisiran fits would require experience beyond controlled trial conditions. Habib explained that background therapies generally remain stable during trials, whereas clinicians often adjust multiple treatments in practice.

“We also have a lot of learning to do ourselves on how we’re going to use this,” he said.

If approved, pharmacists could help translate that learning into coordinated care by tracking vaccination requirements and reinforcing infection-risk counseling. Hospitalization findings broaden the conversation about treatment benefit; careful communication remains essential while cemdisiran’s clinical role is established.

REFERENCES

1. Cemdisiran, dosed subcutaneously every 12 weeks, demonstrates rapid, deep and sustained disease control in generalized myasthenia gravis (gMG) phase 3 trial. News release. Regeneron Pharmaceuticals. April 21, 2026. Accessed October 14, 2026. https://investor.regeneron.com/news-releases/news-release-details/cemdisiran-dosed-subcutaneously-every-12-weeks-demonstrates

2. Cemdisiran regulatory submissions accepted for review by FDA and EMA for the treatment of generalized myasthenia gravis (gMG). News release. Regeneron Pharmaceuticals. June 22, 2026. Accessed October 14, 2026. https://investor.regeneron.com/news-releases/news-release-details/cemdisiran-regulatory-submissions-accepted-review-fda-and-ema

3. A study to test how safe pozelimab and cemdisiran combination therapy and cemdisiran alone are and how well they work in adult patients with generalized myasthenia gravis. UC Irvine clinical trials. Updated July 1, 2026. Accessed October 14, 2026. https://clinicaltrials.icts.uci.edu/trial/NCT05070858

4. Clinical guidance for managing meningococcal disease risk in patients receiving complement inhibitor therapy. CDC. March 6, 2026. Accessed October 14, 2026. https://www.cdc.gov/meningococcal/hcp/clinical-guidance/complement-inhibitor.html